

CAMZYOS® (mavacamten) PATIENT CARD



Patient instructions: Carry this card with you **at all times**. Tell any healthcare professional who sees you that you are taking CAMZYOS and show them this card.

CAMZYOS is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Refer to the Patient Guide for more information, or contact your doctor for more information.

Safety information for patients of childbearing potential:

- CAMZYOS may cause harm to an unborn baby if used during pregnancy
- CAMZYOS must not be taken if you are pregnant or are of childbearing potential and are not using effective contraception
- If you are at childbearing potential, you must use effective contraception throughout treatment and for 4 months after your last dose
- Talk to your doctor if you are considering becoming pregnant
- If you suspect that you may be pregnant or are pregnant, you must inform your prescriber or doctor **immediately**

Safety information for all patients:

- Tell your prescriber or doctor or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, a racing heart (palpitations), or leg swelling
- Tell your prescriber or doctor of any new or existing medical conditions
- Tell your prescriber, doctor or pharmacist before starting new medicines (including prescription and those available over the counter) or herbal supplements. Do not stop taking or change the dose of any medicine or herbal supplement that you are already taking without talking to your doctor or pharmacist first as other medicines can affect how well CAMZYOS works (examples of medicines and products that may affect CAMZYOS are provided in Table 1)
- Tell any healthcare professional who sees you if any side effects occur while you are taking CAMZYOS
- Remember to keep all appointments, especially echocardiogram (also known as echo) appointments, to monitor your heart's health

Safety information for healthcare providers:

- This patient has been prescribed with CAMZYOS (mavacamten)
- Safety concerns associated with CAMZYOS include heart failure due to systolic dysfunction, drug interactions with CYP2C19 and CYP3A4 inducers and inhibitors, and embryo-fetal toxicity
- Please be aware of medicines and supplements that may interact with CAMZYOS
- CAMZYOS is contraindicated with concomitant use of moderate to strong CYP2C19 inhibitors or strong CYP3A4 inhibitors, as well as moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
- Dose adjustments for CAMZYOS are required for patients who are initiated on weak CYP2C19 inhibitors or moderate CYP3A4 inhibitors
- For further information on CAMZYOS treatment, please refer to CAMZYOS Singapore Full Prescribing Information or contact the patient’s treating physician

Table 1: Examples of medicines and products that may affect CAMZYOS

Medicines/products	Condition treated
Omeprazole, esomeprazole	Gastric ulcers and acid reflux
Clarithromycin, rifampicin	Bacterial infections
Verapamil, diltiazem	Heart conditions
Fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole	Fungal infections
Fluoxetine, fluvoxamine	Depression
Ritonavir, cobicistat	Human immunodeficiency virus (HIV)
Telaprevir	Hepatitis C
Grapefruit juice	

Please complete this section or ask your prescriber of CAMZYOS to complete it.

Patient’s name: _____

Name of prescriber: _____

Office phone number: _____

After-hours phone number: _____

Hospital/Clinic name (if applicable): _____